Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05717153 · ClinicalTrials.gov registry record · Early Phase 1

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

A Early Phase 1 study of Malignant Glioma and Diffuse Glioma, sponsored by Mayo Clinic.

Recruiting
Registry status
Early Phase 1
Development phase
18
Enrollment target
1
Study location

NCT05717153 is a Early Phase 1 study of Malignant Glioma and Diffuse Glioma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 18 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05717153, a Early Phase 1 study of Malignant Glioma and Diffuse Glioma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Early Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.

Conditions Studied

Malignant Glioma Diffuse Glioma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging
  • DRUG Eflornithine
  • DRUG Polyamine Transport Inhibitor AMXT-1501 Dicaprate

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-10-01
Est. Completion 2027-09-15
Phase Early Phase 1

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05717153

The ClinicalTrials.gov registry entry for NCT05717153 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (80% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Malignant Glioma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT05717153 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05717153 about?

NCT05717153 is a clinical study titled "Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma". This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irrever...

What is the current status of trial NCT05717153?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2023-10-01. Estimated completion is 2027-09-15.

What conditions does trial NCT05717153 study?

This clinical trial studies the following conditions: Malignant Glioma, Diffuse Glioma.

What interventions are being tested in trial NCT05717153?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Eflornithine (DRUG), Polyamine Transport Inhibitor AMXT-1501 Dicaprate (DRUG).

Who is sponsoring clinical trial NCT05717153?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05717153 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Glioma

All registered trials for this condition

Diffuse Glioma

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.